Dexcom Inc. stock gains on fresh Truist and TD Cowen price targets
Published on 09/19/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Dexcom Inc. stock (ISIN US2521311074) is trading around USD 89 on Nasdaq as of September 19, 2026, leaving the continuous glucose monitoring specialist valued at more than USD 33 billion and supported by fresh analyst price target increases.
Analyst price targets move higher
According to GuruFocus on September 18, 2026, Truist Securities maintained its Buy rating on Dexcom and raised the price target to USD 102.00, up 9.68% from the previous target of USD 93.00.
The same analysis notes that, at a current price of about USD 89.10, Dexcom is trading roughly 13.2 percent below a GF Value estimate of USD 102.62, suggesting valuation headroom if the company delivers on growth expectations, according to GuruFocus.
TD Cowen and broader consensus
TD Cowen has also reiterated a positive stance: as TradingView reported on September 18, 2026, TD Cowen reiterated its Buy rating on Dexcom stock with a price target of USD 95.00, implying about 8.0 percent upside from the September 17, 2026, close of USD 87.93.
Broader analyst consensus remains constructive. According to MarketBeat, Dexcom carries a consensus rating of Moderate Buy with an average price target of USD 88.71, based on 26 analysts, including 2 strong buy, 21 buy, 2 hold and 1 sell recommendations.
Recent price performance and valuation
Per Nasdaq data cited by MarketBeat, Dexcom shares closed at USD 87.93 on Nasdaq on September 17, 2026, a 0.68 percent gain for the session, before extending modestly in extended trading.
Over a longer horizon, Dexcom stock has advanced from USD 66.37 on January 1, 2026 to USD 87.93 as of September 17, 2026, an increase of about 32.5 percent that reflects investor confidence in the company’s continuous glucose monitoring franchise, according to MarketBeat.
Profitability metrics and growth context
Fundamentally, Dexcom presents robust profitability. According to data compiled by MarketBeat, over the trailing twelve months the company generated net income of USD 836.30 million, equivalent to a net margin of 20.12 percent, with a return on equity of 35.94 percent and return on assets of 14.75 percent.
The same overview places Dexcom’s trailing twelve-month earnings per share at USD 2.53 and its trailing price-to-earnings ratio around 34.76 as of the September 17, 2026, close, indicating that the stock trades at a premium multiple compared with many broader market indices but one that investors appear willing to pay for growth in diabetes technology.
Risk considerations around valuation
While Truist Securities and TD Cowen see further upside, the gap between Dexcom’s current price near USD 89 and the consensus target of USD 88.71 suggests limited near-term upside in the base case, as highlighted by MarketBeat.
For investors, the key risk is that continued premium valuation requires Dexcom to sustain double-digit growth and strong margins in its continuous glucose monitoring systems, leaving the stock vulnerable if competitive pressure or reimbursement changes slow that trajectory.
Stock level remains near recent highs
Dexcom stock is listed on Nasdaq under the ticker DXCM, with the most recent completed regular session closing price of USD 87.93 on September 17, 2026 serving as a reference point just a few percent below recent highs cited around USD 92.59 in the 52-week range, according to MarketBeat.
Dexcom Inc. stock key data
- Company: Dexcom Inc.
- ISIN: US2521311074
- Ticker: DXCM
- Trading venue: Nasdaq
- Price (as of September 17, 2026, 16:00): 87.93 USD
- Market capitalization: 33.18 billion USD (as of September 17, 2026)
- Sector / Industry: Health care / Medical devices
- Index membership: S&P 500
